BCRX BioCryst Corp: רווח נקי למניה ב-12 החודשים האחרונים

BioCryst generates revenue through the implementation of innovative treatments, with sales of ORLADEYO tablets for hereditary angioedema serving as the primary profit driver. The current YoY EPS shift over the last 12 months illustrates financial trends, while the -3039.60 metric reflects current dynamics. High business scalability is ensured by the low-cost logistics of oral dosage forms, and the implementation of autonomous robotic filling lines minimizes personnel errors during production.

Year-over-year (YoY) EPS growth (TTM) measures the change in net profit per share over the last twelve months relative to the same period last year, reflecting capital generation efficiency. By analyzing the history of EPS YoY (TTM) percentage changes, an investor can see the results of BioCryst cost optimization through the outsourcing of distribution to third-party logistics operators, which reduces operational risks and increases profitability.